The number of heart attack patients seeking urgent hospital care has dropped by more than 50% worldwide during the COVID-19 outbreak, according to a survey by the European Society of Cardiology (ESC). The survey of 3,101 healthcare professionals in 141 countries was conducted in mid-April.The findings are published in European Heart Journal — Quality of Care and […]
European Society of Cardiology
ESC guidelines updated to include subcutaneous defibs
The European Society of Cardiology updated its treatment guidelines for ventricular arrhythmia patients to include subcutaneous implantable cardioverter defibrillators. The announcement was made at the society’s annual meeting in London on Saturday. The new guidelines recommend the use of the S-ICD units as a possible alternative to transvenous defibrillators in patients with an ICD indication […]
Medtronic’s renal denervation no better at 1 year, researchers say
St. Jude cries victory with its quadripolar leads
Medical device giant St. Jude Medical (NYSE:STJ) had high praise for its own quadripolar leads, saying that blow away any competition from older bipolar leads.
Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves
Study: Remotely monitored heart patients live longer
Heart failure patients with implant-based remote monitoring die less frequently from any cause, according to Biotronik study results released at the European Society of Cardiology congress in Amsterdam.
TAVI: Edwards Lifesciences’ Sapien valve safe for redos, may lower diabetic death toll
ESC 2013: Pacemakers set life expectancy back to normal, researchers say
A slow heart rhythm puts patients at risk of early death, but a cardiac implant may help reset those odds, according to a Dutch study presented this week at the European Society of Cardiology Congress in Amsterdam.
A study of pacemakers in 23 Dutch hospitals found that devices implanted to treat slow heart rhythm helped restore normal life expectancy.
ESC 2013: Medtronic’s Symplicity hypertension treatment still promising at 1 and 3 years
New data on Medtronic’s (NYSE:MDT) Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week.